TREM2 Agonism to Restore Microglial Phagocytosis Across Both Pathologies
Hypothesis Overview
The progressive nature of Alzheimer's disease (AD) is driven not by a single pathological entity but by the synergistic interaction between amyloid-beta (Aβ) accumulation and tau pathology. This duality has confounded therapeutic strategies targeting either protein in isolation. Emerging evidence positions microglial immune dysfunction—specifically, impaired signaling through the triggering receptor expressed on myeloid cells 2 (TREM2) pathway—as a critical upstream mechanism that impairs the brain's capacity to clear both Aβ plaques and tau seeds. Small-molecule TREM2 agonists represent a therapeutic approach with the potential to restore microglial phagocytic capacity across both pathologies, offering synergistic benefit when combined with existing antibody-based therapies.
Molecular Mechanism of TREM2 Signaling
TREM2 is a surface receptor expressed predominantly by microglia in the central nervous system, functioning as a master regulator of microglial responses to pathological stimuli. Under physiological conditions, TREM2 recognizes lipid-bound structures暴露ed on apoptotic cells, apolipoprotein E-containing lipoproteins, and modified self-proteins including Aβ oligomers and pathological tau conformers.
The TREM2 signaling cascade operates through recruitment of the adaptor protein TYROBP (also known as DAP12), which contains an immunoreceptor tyrosine-based activation motif (ITAM). Upon ligand engagement, TYROBP undergoes phosphorylation, creating docking sites for spleen tyrosine kinase (SYK). Activated SYK subsequently phosphorylates phospholipase C gamma 2 (PLCG2), triggering downstream cascades including PI3K/AKT and MAPK pathways that culminate in cytoskeletal reorganization essential for phagocytosis.
Critically, TREM2 signaling drives a fundamental metabolic reprogramming in microglia, shifting cellular energetics toward glycolysis to meet the bioenergetic demands of particle engulfment and processing. This metabolic adaptation is associated with acquisition of a disease-protective phenotype characterized by enhanced survival, increased process motility, and elevated phagocytic capacity. Research indicates that the PLCG2 gain-of-function variant P522R confers enhanced microglial survival and phagocytic activity, providing a genetic basis for the protective effects of this signaling axis.
The actin remodeling required for phagosome formation is orchestrated through SYK-mediated activation of downstream effectors including VAV family guanine nucleotide exchange factors, which regulate the Rho GTPases RAC1 and CDC42. This actin machinery enables the membrane extension and closure events that constitute the final stages of particle internalization. Studies have demonstrated that disruption of any node within this pathway—TREM2, TYROBP, SYK, or PLCG2—results in impaired phagocytic function, establishing the pathway's non-redundant nature in microglial clearance.
Evidence Supporting TREM2 Dysfunction in Alzheimer's Disease
Human postmortem studies have revealed reduced TREM2 expression and signaling in AD brains, with the most pronounced deficits observed in regions of greatest pathology. Single-nucleus RNA sequencing has demonstrated that TREM2-associated gene signatures are diminished in AD microglia, correlating with disease severity. Experimental models confirm that TREM2 deficiency causes microglia to adopt a state permissive for pathology accumulation—TREM2 knockout mice show accelerated Aβ plaque formation, while selective TREM2 deletion in adult mice impairs microglial response to developing plaques.
The mechanism of dysfunction extends beyond simple receptor loss. Studies indicate that AD microglia exhibit splicing alterations favoring production of soluble TREM2 (sTREM2), a decoy variant that competes with membrane-bound receptor for ligand binding without transmitting intracellular signals. This decoy mechanism functionally antagonizes TREM2 signaling, contributing to the apparent "inflammasome exhaustion" observed in aged and AD-affected brains. Furthermore, many AD-risk polymorphisms in TREM2—including R47H and R62H—impair ligand binding affinity, reducing signaling efficacy without abolishing receptor expression.
Research has also identified a compensatory recruitment phase in which disease-associated microglia (DAM) expressing elevated TREM2 levels surround Aβ plaques, yet this response is ultimately insufficient to prevent pathology progression. Tau pathology appears to suppress TREM2-dependent functions through mechanisms involving colony-stimulating factor 1 receptor (CSF1R) signaling alterations and metabolic dysfunction, creating a state where microglial capacity for tau seed clearance becomes severely compromised.
Dual-Pathology Therapeutic Implications
TREM2 agonism offers several mechanistic advantages for addressing the Aβ-tau synergy that defines AD progression. First, restoration of microglial phagocytic capacity directly targets the upstream immune dysfunction that permits accumulation of both proteinaceous aggregates. Enhanced TREM2 signaling promotes microglial clustering around plaques, where these cells can perform protective functions including Aβinternalization and enzymatic degradation. Studies in mouse models demonstrate that pharmacological TREM2 activation reduces plaque burden and associated neuritic dystrophy.
Second, TREM2 agonism enhances microglial clearance of extracellular tau seeds—the transmissible oligomeric species believed to drive spreading of neurofibrillary pathology. TREM2-activated microglia exhibit improved uptake of tau aggregates and more efficient lysosomal degradation, potentially interrupting the templated propagation that characterizes tau pathology progression. This dual capacity positions TREM2 agonism as a single intervention addressing both major proteinopathies in AD.
Third, the immunomodulatory effects of TREM2 agonism may reduce neurotoxic microglial states that contribute to tau pathology progression independently of Aβ. TREM2 signaling suppresses production of pro-inflammatory cytokines including IL-1β and TNF-α while promoting anti-inflammatory functions, potentially creating a microenvironment less permissive to tau hyperphosphorylation and aggregation.
Combination strategies leveraging TREM2 agonism with Aβ-targeting antibodies represent a particularly promising approach. Antibody-mediated opsonization of Aβ enhances microglial recognition through Fc gamma receptors, but this effect depends on intact phagocytic machinery. By restoring microglial clearance capacity, TREM2 agonism could synergize with antibodies to maximize Aβ removal while preventing the inflammatory side effects that have complicated previous therapeutic approaches.
Challenges and Limitations
Several factors complicate clinical translation of TREM2 agonism. The dose-response relationship for TREM2 activation is non-linear, with evidence suggesting that excessive stimulation may paradoxically impair microglial function or promote pathological activation states. Animal models indicate that complete microglial depletion or TREM2 knockout accelerates Aβ accumulation, suggesting that baseline TREM2 function maintains plaque containment—agonist therapy must therefore restore rather than maximally activate signaling.
The temporal window for therapeutic intervention remains uncertain. TREM2-dependent microglial responses may be most effective during early amyloid accumulation, with diminishing benefit once tau pathology is established as the primary driver of cognitive decline. Human clinical trials will need to establish optimal treatment timing relative to disease stage.
Microglial heterogeneity introduces additional complexity. Studies using single-cell approaches have identified multiple disease-associated microglial states, not all of which respond uniformly to TREM2 modulation. Identifying the specific microglial subpopulations most responsive to agonism—and avoiding activation of potentially harmful states—represents a significant pharmacological challenge.
Individual genetic variation in TREM2 and its signaling components will likely influence therapeutic response. AD-risk variants may not respond equally to pharmacological agonism, necessitating biomarker-based patient stratification. The role of peripheral immune cells expressing TREM2 also requires consideration, as systemic effects could contribute to adverse events.
Finally, TREM2 agonism addresses immune dysfunction but does not directly reverse established neurodegeneration. As such, combination approaches targeting multiple disease mechanisms may be necessary to achieve meaningful clinical benefit. The interaction between TREM2 agonism and co-pathologies including TDP-43 proteinopathy—which occurs in a substantial proportion of AD cases—remains to be established.
Conclusion
TREM2 agonism represents a compelling therapeutic strategy addressing the upstream immune dysfunction that permits Aβ-tau synergy in Alzheimer's disease. By restoring microglial phagocytic capacity for both proteinopathies, agonists targeting the TREM2-TYROBP-PLCG2-SYK axis could provide disease-modifying benefit as monotherapy while offering particular synergy when combined with Aβ-targeting antibodies. Successful translation will require careful attention to dosing, patient selection, and treatment timing relative to disease progression.